Nykode Therapeutics ASA
Research Nykode Therapeutics ASA (NYKD) on Bullrun: market cap NOK 1.04B, dividend yield 30.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNYKD
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 1.04B
- Dividend yield30.8%
- Financial periodQ4 2025
- Net income-NOK 8.00M
- Free cash flow-NOK 5.17M
Valuation Snapshot
latest market cap is NOK 1.04B; dividend yield is 30.8%.
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial;
Frequently asked questions
What is Nykode Therapeutics ASA's market cap?
Nykode Therapeutics ASA's market capitalization is NOK 1.04B.
Does Nykode Therapeutics ASA pay a dividend?
Nykode Therapeutics ASA has a dividend yield of 30.8%.
What does Nykode Therapeutics ASA do?
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases.